These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 8481896)
1. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue. Nakada SY; di Sant'Agnese PA; Moynes RA; Hiipakka RA; Liao S; Cockett AT; Abrahamsson PA Cancer Res; 1993 May; 53(9):1967-70. PubMed ID: 8481896 [TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features. Alberti C G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206 [TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status. Bonkhoff H Prostate Suppl; 1998; 8():18-22. PubMed ID: 9690659 [TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation. Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ Cancer Res; 2000 Feb; 60(3):741-8. PubMed ID: 10676662 [TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Xing N; Qian J; Bostwick D; Bergstralh E; Young CY Prostate; 2001 Jun; 48(1):7-15. PubMed ID: 11391682 [TBL] [Abstract][Full Text] [Related]
7. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects. Mosca A; Berruti A; Russo L; Torta M; Dogliotti L J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. Wafa LA; Palmer J; Fazli L; Hurtado-Coll A; Bell RH; Nelson CC; Gleave ME; Cox ME; Rennie PS Hum Pathol; 2007 Jan; 38(1):161-70. PubMed ID: 16997353 [TBL] [Abstract][Full Text] [Related]
9. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications. Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178 [TBL] [Abstract][Full Text] [Related]
11. Localization of immunoreactive HIF-1alpha and HIF-2alpha in neuroendocrine cells of both benign and malignant prostate glands. Monsef N; Helczynski L; Lundwall A; Påhlman S; Prostate; 2007 Aug; 67(11):1219-29. PubMed ID: 17562539 [TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine differentiation in the progression of prostate cancer. Komiya A; Suzuki H; Imamoto T; Kamiya N; Nihei N; Naya Y; Ichikawa T; Fuse H Int J Urol; 2009 Jan; 16(1):37-44. PubMed ID: 19120524 [TBL] [Abstract][Full Text] [Related]
14. Biologic markers in prostatic intraepithelial neoplasia: immunohistochemical and cytogenetic analyses. Tsuji M; Kanda K; Murakami Y; Kurokawa Y; Kanayama H; Sano T; Kagawa S J Med Invest; 1999 Feb; 46(1-2):35-41. PubMed ID: 10408155 [TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Huang J; Yao JL; di Sant'Agnese PA; Yang Q; Bourne PA; Na Y Prostate; 2006 Sep; 66(13):1399-406. PubMed ID: 16865726 [TBL] [Abstract][Full Text] [Related]
16. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors. Cussenot O; Villette JM; Cochand-Priollet B; Berthon P Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663 [TBL] [Abstract][Full Text] [Related]
17. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359 [TBL] [Abstract][Full Text] [Related]
18. [The influence of neuroendocrine differentiation on the growth and androgen receptor expression of prostate carcinoma cells]. Song Y; Wu G; Xin DQ; Na YQ Zhonghua Wai Ke Za Zhi; 2004 Dec; 42(23):1453-6. PubMed ID: 15733464 [TBL] [Abstract][Full Text] [Related]
19. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cox ME; Deeble PD; Lakhani S; Parsons SJ Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001 [TBL] [Abstract][Full Text] [Related]
20. Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy. Van der Kwast TH; Têtu B; Fradet Y; Dupont A; Gomez J; Cusan L; Diamond P; Labrie F Prostate; 1996 Apr; 28(4):227-31. PubMed ID: 8602398 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]